Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
As of close of business last night, Recursion Pharmaceuticals Inc’s stock clocked out at $6.88, down -5.23% from its previous closing price of $7.26. In other words, the price has decreased by -$5.23 from its previous closing price. On the day, 14.07 million shares were traded. RXRX stock price reached its highest trading level at $7.07 during the session, while it also had its lowest trading level at $6.78.
Ratios:
To gain a deeper understanding of RXRX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.35 and its Current Ratio is at 4.35. In the meantime, Its Debt-to-Equity ratio is 0.17 whereas as Long-Term Debt/Eq ratio is at 0.14.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on May 22, 2023, initiated with a Equal-Weight rating and assigned the stock a target price of $8.
On March 16, 2023, Needham started tracking the stock assigning a Buy rating and target price of $17.
On September 16, 2022, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $20.KeyBanc Capital Markets initiated its Overweight rating on September 16, 2022, with a $20 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 10 ’25 when Gibson Christopher bought 20,000 shares for $7.05 per share.
Gibson Christopher bought 20,000 shares of RXRX for $146,200 on Jan 08 ’25. On Dec 26 ’24, another insider, Marriott Tina, who serves as the Officer of the company, bought 6,000 shares for $7.46 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RXRX now has a Market Capitalization of 2688167168 and an Enterprise Value of 1636425088. For the stock, the TTM Price-to-Sale (P/S) ratio is 41.25 while its Price-to-Book (P/B) ratio in mrq is 3.75. Its current Enterprise Value per Revenue stands at 25.105 whereas that against EBITDA is -4.494.
Stock Price History:
The Beta on a monthly basis for RXRX is 0.85, which has changed by -0.3605948 over the last 52 weeks, in comparison to a change of 0.22263205 over the same period for the S&P500. Over the past 52 weeks, RXRX has reached a high of $15.74, while it has fallen to a 52-week low of $5.60. The 50-Day Moving Average of the stock is -0.45%, while the 200-Day Moving Average is calculated to be -9.09%.
Shares Statistics:
It appears that RXRX traded 11.16M shares on average per day over the past three months and 15670450 shares per day over the past ten days. A total of 390.76M shares are outstanding, with a floating share count of 323.50M. Insiders hold about 17.21% of the company’s shares, while institutions hold 57.88% stake in the company. Shares short for RXRX as of 1734048000 were 67097533 with a Short Ratio of 6.61, compared to 1731628800 on 64573303. Therefore, it implies a Short% of Shares Outstanding of 67097533 and a Short% of Float of 18.72.
